文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Evidence-Based Review on Symptomatic Management of Huntington's Disease.

作者信息

Shin Jung Hwan, Yang Hui-Jun, Ahn Jong Hyun, Jo Sungyang, Chung Seok Jong, Lee Jee-Young, Kim Hyun Sook, Kim Manho

机构信息

Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.

Department of Neurology, Ulsan University Hospital, Ulsan, Korea.

出版信息

J Mov Disord. 2024 Oct;17(4):369-386. doi: 10.14802/jmd.24140. Epub 2024 Aug 9.


DOI:10.14802/jmd.24140
PMID:39117301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11540544/
Abstract

Huntington's disease (HD) is a neurodegenerative disorder characterized by motor, behavioral, and cognitive impairments and significant impacts on patient quality of life. This evidence-based review, conducted by the Korean Huntington Disease Society task force, systematically examines current pharmacological and nonpharmacological interventions for symptomatic management of HD. Following PRISMA guidelines, databases were searched for studies up to August 2022 that focused on 23 symptoms across four domains: motor, neuropsychological, cognition, and others. This review provides a comprehensive and systematic approach to the management of HD, highlighting the need for more high-quality clinical trials to develop robust evidence-based guidelines.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a2/11540544/e8f4f3e12429/jmd-24140f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a2/11540544/81cfccd3287f/jmd-24140f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a2/11540544/e8f4f3e12429/jmd-24140f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a2/11540544/81cfccd3287f/jmd-24140f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06a2/11540544/e8f4f3e12429/jmd-24140f2.jpg

相似文献

[1]
Evidence-Based Review on Symptomatic Management of Huntington's Disease.

J Mov Disord. 2024-10

[2]
Antidopaminergic medications in Huntington's disease.

J Huntingtons Dis. 2025-2

[3]
Survey of the Huntington's Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs.

J Huntingtons Dis. 2016-12-15

[4]
Is deep brain stimulation effective in Huntington's Disease? - a systematic literature review.

Neurol Neurochir Pol. 2022

[5]
The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease.

Parkinsonism Relat Disord. 2018-1-5

[6]
Meaningful and Measurable Health Domains in Huntington's Disease: Large-Scale Validation of the Huntington's Disease Health-Related Quality of Life Questionnaire Across Severity Stages.

Value Health. 2019-6

[7]
Cognitive Dysfunction Contributes to Mobility Impairments in Huntington's Disease.

J Huntingtons Dis. 2017

[8]
Risk Factors and Interventions for Suicide in Huntington's Disease-A Systematic Review.

J Clin Med. 2024-6-12

[9]
Huntington Study Group's Neuropsychology Working Group: Implementing Non-Motor Diagnostic Criteria.

Mov Disord Clin Pract. 2023-11-8

[10]
Clinical diagnosis and management in early Huntington's disease: a review.

Degener Neurol Neuromuscul Dis. 2015-3-25

引用本文的文献

[1]
A Practical Guide for Diagnostic Investigations and Special Considerations in Patients With Huntington's Disease in Korea.

J Mov Disord. 2025-1

本文引用的文献

[1]
Huntington disease - Update on ongoing therapeutic developments and a look toward the future.

Parkinsonism Relat Disord. 2024-5

[2]
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research.

Int J Mol Sci. 2023-8-21

[3]
Pain in Huntington's disease and its potential mechanisms.

Front Aging Neurosci. 2023-7-6

[4]
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet Neurol. 2023-6

[5]
Increased 10-Year Prevalence of Huntington's Disease in South Korea: An Analysis of Medical Expenditure Through the National Healthcare System.

J Clin Neurol. 2023-3

[6]
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.

CNS Drugs. 2022-11

[7]
Use of Objective Outcomes Measures to Verify the Effects of ICF-Based Gait Treatment in Huntington's Disease Patient on Globus Pallidus Deep Brain Stimulation: A Case Report.

Front Rehabil Sci. 2022-4-14

[8]
Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta-Analysis.

Mov Disord. 2022-12

[9]
Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration-QTc Analysis.

Clin Pharmacol Drug Dev. 2023-1

[10]
Time-Restricted Ketogenic Diet in Huntington's Disease: A Case Study.

Front Behav Neurosci. 2022-7-29

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索